These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 24929163)

  • 1. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validating impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Le LW; Bezjak A; MacRae R; Hope AJ; Pantarotto J
    Thorac Cancer; 2021 Jan; 12(2):201-209. PubMed ID: 33258301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.
    Parks J; Kloecker G; Woo S; Dunlap NE
    Am J Clin Oncol; 2016 Apr; 39(2):147-53. PubMed ID: 24457534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
    Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Xiao Y; Grills IS
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1074-81. PubMed ID: 23154077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
    Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
    Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
    Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
    Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size.
    Marwaha G; Stephans KL; Woody NM; Reddy CA; Videtic GM
    J Thorac Oncol; 2014 Nov; 9(11):1693-7. PubMed ID: 25185531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Koshy M; Malik R; Weichselbaum RR; Sher DJ
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):344-50. PubMed ID: 25636759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. It's never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival.
    Roach MC; Rehman S; DeWees TA; Abraham CD; Bradley JD; Robinson CG
    Pract Radiat Oncol; 2016; 6(1):12-8. PubMed ID: 26598909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy.
    Liao ZX; Komaki RR; Thames HD; Liu HH; Tucker SL; Mohan R; Martel MK; Wei X; Yang K; Kim ES; Blumenschein G; Hong WK; Cox JD
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):775-81. PubMed ID: 19515503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.